Article
The defined TLR3 agonist, Nexavant, exhibits anti-cancer efficacy and potentiates…
medRxiv · 2023 · Kim, D.; Lee, S.-H.; Choi, Y.-H.; Kang, S.-M.; Lee, M.-G. L.; Hong, S.-B.; Perouzel, E.; Debin, A.
Key facts
| Title | The defined TLR3 agonist, Nexavant, exhibits anti-cancer efficacy and potentiates anti-PD-1 antibody therapy by enhancing immune cell infiltration. |
|---|---|
| First author | Kim, D.; Lee, S.-H.; Choi, Y.-H.; Kang, S.-M.; Lee, M.-G. L.; Hong, S.-B.; Perouzel, E.; Debin, A. |
| Journal | medRxiv |
| Published | Oct 30, 2023 |
| DOI | 10.1101/2023.10.25.564097 |
| Devices mentioned | 103132 |
| Product codes mentioned | JCJ, MVU |
At a glance
- 1–9 FDA submissions mentioned
- 1–9 Product codes mentioned
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Literature
Peer-reviewed and preprint literature indexed by Orca1 and linked to the FDA submissions and product codes each article mentions. Only bibliographic details are shown here.
Source: Publisher and PubMed metadata; device mentions identified by Orca1